Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-0547

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71335-0547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713350547)

Label for Valsartan Hctz 320/25mg tablet by Bryant Ranch Prepack. The label includes storage instructions at 20°-25°C, a comparison to Diovan Hctz 320/25mg by Macleods Pharmaceuticals Ltd., a quantity of 30 tablets, and an NDC of 71335-0547. It is marked RX only and includes warnings to keep drugs out of reach of children.*

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

A line graph showing the percentage of patients with baseline systolic blood pressure (SBP) below 140 mmHg, plotted against baseline SBP values ranging from 140 to 180 mmHg. Four treatment groups are compared: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The graph illustrates the relative efficacy of each treatment in lowering SBP below 140 mmHg.*

FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

A line graph showing the percentage of patients with diastolic blood pressure less than 90 mmHg (%) versus baseline diastolic blood pressure (mmHg). The graph compares effects of Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo on blood pressure control, with each represented by distinct markers.*

FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

A line graph comparing the percentage of subjects achieving systolic blood pressure below 130 mmHg (% SBP <130) against baseline systolic blood pressure (SBP in mmHg). It includes curves for Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, illustrating the effectiveness of each treatment relative to baseline SBP values.*

FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

A line graph comparing the percentage of diastolic blood pressure below 80 mmHg (% DBP<80) against the baseline diastolic blood pressure (DBP) in mmHg. The graph includes four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, each represented by different markers to show their efficacy across DBP baselines.*

FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Chemical structure diagram showing the molecular arrangement of the active ingredient in Valsartan and Hydrochlorothiazide. The diagram depicts a benzene ring with chlorine, sulfonamide, and other functional groups attached, illustrating the chemical composition of this medication.*

FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Chemical structure of the active ingredient in Valsartan and Hydrochlorothiazide, depicting the molecular formula with aromatic rings, a carboxylic acid group, and characteristic side chains visible in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.